FR2505656A1 - Composition therapeutique a base de sulfate de chondroitine actif a et /ou c - Google Patents
Composition therapeutique a base de sulfate de chondroitine actif a et /ou c Download PDFInfo
- Publication number
- FR2505656A1 FR2505656A1 FR8201965A FR8201965A FR2505656A1 FR 2505656 A1 FR2505656 A1 FR 2505656A1 FR 8201965 A FR8201965 A FR 8201965A FR 8201965 A FR8201965 A FR 8201965A FR 2505656 A1 FR2505656 A1 FR 2505656A1
- Authority
- FR
- France
- Prior art keywords
- implant
- composition according
- active
- transplant
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title description 5
- 239000007943 implant Substances 0.000 claims abstract description 24
- 241000282414 Homo sapiens Species 0.000 claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims abstract description 11
- 238000000576 coating method Methods 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 210000000056 organ Anatomy 0.000 claims abstract description 6
- 238000002054 transplantation Methods 0.000 claims abstract description 6
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims abstract description 5
- 238000002513 implantation Methods 0.000 claims abstract description 4
- 230000000399 orthopedic effect Effects 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000007928 intraperitoneal injection Substances 0.000 claims abstract 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 8
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 7
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000008174 sterile solution Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 241000997494 Oneirodidae Species 0.000 claims 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000004053 dental implant Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000007560 devascularization Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26378881A | 1981-05-14 | 1981-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2505656A1 true FR2505656A1 (fr) | 1982-11-19 |
Family
ID=23003232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8201965A Pending FR2505656A1 (fr) | 1981-05-14 | 1982-02-08 | Composition therapeutique a base de sulfate de chondroitine actif a et /ou c |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS57188522A (sv) |
| CA (1) | CA1179264A (sv) |
| DE (1) | DE3144236A1 (sv) |
| DK (1) | DK70382A (sv) |
| FR (1) | FR2505656A1 (sv) |
| GB (1) | GB2098506B (sv) |
| SE (1) | SE8107352L (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0121008A3 (en) * | 1983-03-29 | 1985-03-27 | Marcel E. Nimni | Coating for bioprosthetic device and method of making same |
| AU4278793A (en) * | 1992-04-07 | 1993-11-08 | Wilhelm Environmental Technologies, Inc. | Flue gas conditioning system |
| GB2297931B (en) * | 1992-04-07 | 1996-10-16 | Wilhelm Env Tech Inc | Flue gas conditioning system |
| WO2000027437A2 (en) * | 1998-11-11 | 2000-05-18 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2055872A (en) * | 1979-10-05 | 1981-03-11 | Biomed Res Inc | Preparation of chondroitin sulphate(s) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3895106A (en) * | 1970-04-15 | 1975-07-15 | Morrison L M | Novel CSA and CSC for use in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals |
| DE2037942C2 (de) * | 1970-04-15 | 1982-11-18 | Biomed Research, Inc., 90048 Los Angeles, Calif. | Arzneimittel enthaltend ein "aktives" Chondroitinsulfat als Wirkstoff zur Verhinderung des Auftretens atherosklerotischer Läsionen und zur Verhinderung des Auftretens von Herzanfällen |
| JPS5235710A (en) * | 1975-09-16 | 1977-03-18 | Ulvac Corp | In-material-heat reflection plate device in heating furnaces |
-
1981
- 1981-09-10 GB GB8127345A patent/GB2098506B/en not_active Expired
- 1981-10-13 JP JP56162145A patent/JPS57188522A/ja active Pending
- 1981-11-02 CA CA000389215A patent/CA1179264A/en not_active Expired
- 1981-11-06 DE DE19813144236 patent/DE3144236A1/de active Granted
- 1981-12-08 SE SE8107352A patent/SE8107352L/sv not_active Application Discontinuation
-
1982
- 1982-02-08 FR FR8201965A patent/FR2505656A1/fr active Pending
- 1982-02-17 DK DK70382A patent/DK70382A/da not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2055872A (en) * | 1979-10-05 | 1981-03-11 | Biomed Res Inc | Preparation of chondroitin sulphate(s) |
Non-Patent Citations (2)
| Title |
|---|
| CHEMICAL ABSTRACTS, volume 76, no. 1, 3 janvier 1972, page 24, abrégé 213r (COLUMBUS, OHIO, US); M.W. ASHBY et al.: "Use of chondroitin sulfate in prolonging survival of adult skin allografts", & J. Surg. Res. 1971, 11(7), 350-5 * |
| CHEMICAL ABSTRACTS, volume 91, no. 9, 27 août 1979, page 410, abrégé 72448d (COLUMBUS, OHIO, US); L.H. TOLEDO-PEREYRA et al.: "Effect of chondroitin sulfate on the prolongation of kidney allograft survival", & Transplantation 1979, 27(6), 428-30 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3144236A1 (de) | 1982-11-25 |
| GB2098506A (en) | 1982-11-24 |
| GB2098506B (en) | 1984-10-03 |
| DK70382A (da) | 1982-11-15 |
| JPS57188522A (en) | 1982-11-19 |
| CA1179264A (en) | 1984-12-11 |
| SE8107352L (sv) | 1982-11-15 |
| DE3144236C2 (sv) | 1987-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2069450C (fr) | Procede de fabrication d'un materiau pour osteoplastie a partir d'un tissu osseux naturel et materiau obtenu par ce procede | |
| JP5053470B2 (ja) | グラフト・プロテーゼとその材料及び方法 | |
| WO2007017580A2 (fr) | Preparations implantables | |
| Lexer | Free transplantation | |
| US20140106447A1 (en) | Compositions and methods for recruiting stem cells | |
| FR2564732A1 (fr) | Biomatiere osteoformatrice artificielle et son procede de fabrication | |
| EP3349814B1 (en) | Non-gelling soluble extracellular matrix with biological activity | |
| FR2743075A1 (fr) | Procede de preparation de substances actives a partir de la nacre, produits obtenus, utiles notamment comme medicaments | |
| Eskeland et al. | The ultrastructure of normal digital flexor tendon sheath and of the tissue formed around silicone and polyethylene implants in man | |
| WO1999052946A1 (fr) | Procede de sterilisation d'un collagene natif en milieu liquide, collagene natif sterile obtenu, compositions le contenant et applications | |
| FR2505656A1 (fr) | Composition therapeutique a base de sulfate de chondroitine actif a et /ou c | |
| WO2017101027A1 (zh) | 改良的生物医用材料产品 | |
| EP1622596B1 (fr) | Implant injectable de globine insoluble | |
| JP6899455B2 (ja) | 軟骨組織修復用コラーゲンの製造および使用方法 | |
| FR2613620A1 (fr) | Implant destine a la medecine humaine | |
| FR2827478A1 (fr) | Procede de preparation d'une poudre a base de nacre, proteine isolee de ladite poudre et leurs utilisations en chirurgie osseuse et dans diverses pathologies osteoarticulaires | |
| KR20220089586A (ko) | 복합기능성 유착방지용 약학조성물 | |
| FR2667789A1 (fr) | Composition cicatrisante et procede pour sa preparation. | |
| RU2290939C2 (ru) | Средство для лечения повреждений спинного и головного мозга | |
| CN116392642A (zh) | 用于心衰治疗的细胞外基质/糖肽水凝胶及其制备方法 | |
| Cavallaro et al. | Experimental study of the interaction between aortic grafts and the intestine: Dacron vs PTFE | |
| Monhian et al. | The role of soft-tissue implants in scar revision | |
| FR2746652A1 (fr) | Utilisation de la coquille d'oeuf comme implant osseux et son mode de fabrication | |
| RU2053721C1 (ru) | Способ подготовки к протезированию короткой культи бедра | |
| JP2011501677A5 (sv) |